|[January 23, 2014]
XenoPort Announces Pricing of Public Offering of Common Stock
SANTA CLARA, Calif. --(Business Wire)--
XenoPort, Inc. (NASDAQ: XNPT) announced today the pricing of an
underwritten registered public offering of 12,000,000 shares of its
common stock at a price to the public of $6.00 per share. The size of
the offering was increased from the 10,000,000 shares previously
announced. XenoPort has also granted to the underwriters a 30-day option
to purchase up to an additional 1,800,000 shares of its common stock.
All of the shares in the offering are being offered by XenoPort. The
offering is expected to close on or about January 29, 2014, subject to
customary closing conditions.
Credit Suisse Securities (USA) LLC is acting as sole book-running
manager for the offering. RBC Capital Markets, LLC and Wells Fargo (News - Alert)
Securities, LLC are acting as co-managers.
A registration statement relating to the shares described above was
previously filed with, and has been declared effective by, the
Securities and Exchange Commission (SEC (News - Alert)). A final prospectus supplement
related to the offering will be filed with the SEC and will be available
on the SEC's website located at http://www.sec.gov.
Copies of the final prospectus supplement and the accompanying
prospectus relating to this offering, when available may be obtained
from Credit Suisse Securities (USA) LLC, Attention: Prospectus
Department, One Madison Avenue, New York, NY 10010, or by telephone at
(800) 221-1037, or by e-mail at firstname.lastname@example.org.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of, the
shares in any state or other jurisdiction which such offer, solicitation
or sale would be unlawful prior to the registration or qualification
under the securities laws of any such state or other jurisdiction.
XenoPort, Inc. is a biopharmaceutical company focused on developing and
commercializing a portfolio of internally discovered product candidates
for the potential treatment of neurological disorders.
This press release contains "forward-looking" statements, including,
without limitation, all statements related to the offering. Any
statements contained in this press release that are not statements of
historical fact may be deemed to be forward-looking statements. Words
such as "expected," "will" and similar expressions are intended to
identify forward-looking statements. These forward-looking statements
are based upon XenoPort's current expectations. Forward-looking
statements involve risks and uncertainties. XenoPort's actual results
and the timing of events could differ materially from those anticipated
in such forward-looking statements as a result of these risks and
uncertainties, which include, without limitation, risks and
uncertainties associated with market conditions, whether XenoPort will
be able to consummate the offering and the satisfaction of closing
conditions related to the offering. There can be no assurance that
XenoPort will be able to complete the offering. Regardless of whether
the offering is consummated, XenoPort will continue to need additional
funding and may be unable to raise capital when needed, which would
force XenoPort to delay, reduce or eliminate its product development
programs or commercialization efforts. These and other risk factors
related to XenoPort and its business are discussed under the heading
"Risk Factors" in XenoPort's Quarterly Report on Form 10-Q for the
quarter ended September 30, 2013, filed with the SEC on November 8,
2013, and in the preliminary prospectus supplement related to the
offering filed with the SEC on January 21, 2014. XenoPort expressly
disclaims any obligation or undertaking to release publicly any updates
or revisions to any forward-looking statements contained herein to
reflect any change in the company's expectations with regard thereto or
any change in events, conditions or circumstances on which any such
statements are based.
[ Back To TMCnet.com's Homepage ]